The dose for children aged 6-14 years: One tablet chewing 5 mg daily in the evening. Correction dose within this age group is not required.
General recommendations: The therapeutic effect of the drug oral masteron develops in one day. The patient should continue taking the drug Singlon in controlled periods of bronchial asthma, as well as during periods of worsening of the disease.
In patients with renal insufficiency, mild or moderate hepatic impairment dose adjustment is required. Data for patients with severe liver failure absent.
The dose is not dependent on sex of the patient.
Appointed in patients receiving inhaled corticosteroids, it should not be abruptly replaced by inhaled glucocorticosteroids .
The following are adverse reactions by system-organ classes according to MedDRA classification, which often (> 1/100, <1/10) were observed in patients treated with montelukast:
Disorders of the nervous system: headache,
the following adverse events have been identified during post-marketing research:
Violations of the blood and lymphatic system:
increased bleeding tendency.
Violations of the immune system:
hypersensitivity reactions, including anaphylaxis; eosinophilic infiltration of the liver.
sleep oral masteron disturbances, including nightmares, hallucinations, psychomotor hyperactivity (including irritability, restlessness, agitation including aggressive behavior, and tremor), depression, insomnia, suicidal ideation and suicidal behavior.
Disorders of the nervous system:
drowsiness, dizziness, paresthesia / hypersensitivity, seizures.
Violations of the cardiovascular system:
Disorders of the gastrointestinal tract:
diarrhea, dry mouth, dyspepsia, nausea and vomiting.
Violations of the hepatobiliary system:
increased activity of “hepatic” transaminases in serum , cholestatic hepatitis, pancreatitis.
Violations of the skin and subcutaneous tissue:
angioneurotic edema, the appearance of ecchymosis, urticaria, pruritus, rash, erythema nodosum, a tendency to the formation of bruises.
Violations of the musculoskeletal and connective tissue disorders:
arthralgia, myalgia including muscle cramps.
General disorders and administration site at:
. Asthenia / fatigue, discomfort, swelling
in the very rare cases in patients receiving montelukast in patients suffering from bronchial asthma, Churg syndrome develops – Strauss.
No specific information on the treatment of drug overdose oral masteron . In clinical studies of adult patients with asthma take the drug at doses up to 200 mg / day for 22 weeks, and in short studies -. At doses up to 900 mg / day for about one week, without clinically significant adverse events
observed cases of acute montelukast overdose children and adults when receiving a dose greater than 1000 mg (approximately 61 mg / kg for a child aged 42 months).
These clinical and laboratory findings were consistent with the safety profile for adult and pediatric patients. In the majority of overdose reports indicate no adverse symptoms. The most common adverse events consistent with the safety profile of montelukast and included abdominal pain, sleepiness, thirst, headache, vomiting, and psychomotor hyperactivity, mydriasis. There are no data on the possibility of elimination of montelukast in peritoneal dialysis or hemodialysis.